Panther, I am glad you brought up that iron ore experience. What a huge contrast looking at the two penny stocks. One had absolutely nothing going on, no production, no revenues, nothing. Now we have SCRC. With SCRC there exists products and services, real time revenues increasing on a monthly basis, and potential for growth in a diversified business model. I stated a few weeks ago, based on the previous quarters performance, that SCRC would post $2.1M in compounding pharmacy revenues for June. I still believe we will come in pretty close to that number giving us a Q2 total revenue final around $4.5M. No bad for a penny stock. Q2's performance should help us launch out of this .12 to .13 range. How much, anyone's guess. The next big catalyst which should be announced soon would be "cash flow positive". With these revenues I would expect that announcement anytime in the near future.
One thing about the compounding pharmacy revenues. We have seen an explosion of activity in the last five quarters. As the revenue volume continues to grow, I would not expect the 35-60% increases like we've seen. I would guess from this point on a 10% increase in revenues each month. This is true for all companies, as the volume increases the percent increase declines but the volume generated is still very significant.
SCRC is in great shape. I waited this long and I will continue to wait because right now this little stock is tracking at a run rate of $20M a year. This is and will continue to be a great investment.
News 
Market Data 
Discover 
AI
